Ocugen (OCGN) to Release Earnings on Friday

Ocugen (NASDAQ:OCGN) is projected to release its Q1 2025 earnings data before the market opens on Friday, May 9th. Analysts expect Ocugen to post earnings of ($0.06) per share for the quarter.

Ocugen (NASDAQ:OCGN) last released its quarterly earnings results on Wednesday, March 5th. The company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). The business had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.30 million. Ocugen had a negative return on equity of 154.75% and a negative net margin of 532.51%. During the same period in the prior year, the business posted ($0.03) EPS. On average, analysts expect Ocugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ocugen Price Performance

Ocugen stock opened at $0.66 on Thursday. Ocugen has a 1 year low of $0.52 and a 1 year high of $2.06. The company’s 50 day simple moving average is $0.66 and its 200-day simple moving average is $0.77. The company has a market capitalization of $193.35 million, a price-to-earnings ratio of -3.68 and a beta of 4.21. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.58 and a current ratio of 2.58.

Analysts Set New Price Targets

OCGN has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Ocugen in a research report on Thursday, March 6th. Chardan Capital upped their target price on shares of Ocugen from $6.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, March 6th.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.